Vanguard Group
MRNS

Vanguard Group’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Vanguard Group’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,596,768
Closed -$1.39M – 4355
2024
Q4 		$1.39M Sell
2,596,768
-206,197
-7% -$144K ﹤0.01% 3665
2024
Q3 		$4.93M Hold
2,802,965
– – ﹤0.01% 3276
2024
Q2 		$3.28M Sell
2,802,965
-2,955
-0.1% -$7.39K ﹤0.01% 3406
2024
Q1 		$25.4M Buy
2,805,920
+132,689
+5% +$1.29M ﹤0.01% 2480
2023
Q4 		$29.1M Buy
2,673,231
+95,756
+4% +$718K ﹤0.01% 2425
2023
Q3 		$20.7M Buy
2,577,475
+31,233
+1% +$260K ﹤0.01% 2539
2023
Q2 		$27.7M Buy
2,546,242
+361,498
+17% +$3.1M ﹤0.01% 2451
2023
Q1 		$15.1M Buy
2,184,744
+192,655
+10% +$1.21M ﹤0.01% 2730
2022
Q4 		$7.93M Buy
1,992,089
+300,719
+18% +$1.48M ﹤0.01% 3057
2022
Q3 		$11.2M Buy
1,691,370
+16,812
+1% +$104K ﹤0.01% 2905
2022
Q2 		$8.11M Sell
1,674,558
-22,117
-1% -$135K ﹤0.01% 3101
2022
Q1 		$15.9M Buy
1,696,675
+2,557
+0.2% +$25.4K ﹤0.01% 2902
2021
Q4 		$20.1M Sell
1,694,118
-2,126
-0.1% -$24.6K ﹤0.01% 2837
2021
Q3 		$19.3M Sell
1,696,244
-29,506
-2% -$406K ﹤0.01% 2884
2021
Q2 		$31M Buy
1,725,750
+22,761
+1% +$366K ﹤0.01% 2613
2021
Q1 		$26.4M Buy
1,702,989
+124,905
+8% +$1.81M ﹤0.01% 2637
2020
Q4 		$19.3M Buy
1,578,084
+311,512
+25% +$4.34M ﹤0.01% 2649
2020
Q3 		$16.3M Buy
1,266,572
+92,456
+8% +$798K ﹤0.01% 2554
2020
Q2 		$11.9M Buy
1,174,116
+249,466
+27% +$2.29M ﹤0.01% 2678
2020
Q1 		$7.51M Buy
924,650
+49,083
+6% +$425K ﹤0.01% 2753
2019
Q4 		$7.57M Buy
875,567
+304,996
+53% +$1.71M ﹤0.01% 2989
2019
Q3 		$3.52M Sell
570,571
-76,258
-12% -$616K ﹤0.01% 3260
2019
Q2 		$10.7M Buy
646,829
+28,824
+5% +$501K ﹤0.01% 2818
2019
Q1 		$10.3M Buy
618,005
+65,529
+12% +$943K ﹤0.01% 2806
2018
Q4 		$6.34M Buy
552,476
+162,603
+42% +$3.29M ﹤0.01% 2981
2018
Q3 		$15.6M Sell
389,873
-3,447
-0.9% -$98.1K ﹤0.01% 2702
2018
Q2 		$11.1M Buy
393,320
+68,015
+21% +$1.51M ﹤0.01% 2852
2018
Q1 		$4.97M Buy
325,305
+7,474
+2% +$178K ﹤0.01% 3158
2017
Q4 		$10.4M Buy
317,831
+109,015
+52% +$2.94M ﹤0.01% 2799
2017
Q3 		$4.9M Buy
208,816
+62,902
+43% +$705K ﹤0.01% 3129
2017
Q2 		$800K Sell
145,914
-17,499
-11% -$94.6K ﹤0.01% 3617
2017
Q1 		$1.16M Buy
163,413
+116,708
+250% +$627K ﹤0.01% 3540
2016
Q4 		$188K Sell
46,705
-44,720
-49% -$208K ﹤0.01% 3900
2016
Q3 		$665K Buy
91,425
+20,580
+29% +$139K ﹤0.01% 3686
2016
Q2 		$360K Buy
70,845
+1,904
+3% +$35.1K ﹤0.01% 3849
2016
Q1 		$1.48M Buy
68,941
+22,861
+50% +$484K ﹤0.01% 3476
2015
Q4 		$1.41M Buy
46,080
+32,200
+232% +$944K ﹤0.01% 3520
2015
Q3 		$463K Buy
13,880
+5,705
+70% +$322K ﹤0.01% 3869
2015
Q2 		$379K Buy
+8,175
New +$305K ﹤0.01% 3935

Vanguard Group's MRNS Position: Q1 2025 in Review

Vanguard Group sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2025, closing a stake of 2,596,768 shares — an estimated $1.39M sold.

Vanguard Group first reported a position in MRNS in Q2 2015 and held it in 39 quarters. The position peaked at $31M in Q2 2021. 0 funds tracked by Wall St. Rank hold MRNS as of Q1 2025.

  • Vanguard Group reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2025 after selling out during the quarter.
  • Vanguard Group sold 2,596,768 Marinus Pharmaceuticals, Inc shares in Q1 2025, an estimated $1.39M.
  • Vanguard Group first reported a position in Marinus Pharmaceuticals, Inc in Q2 2015 and held it in 39 quarters.
  • Vanguard Group's Marinus Pharmaceuticals, Inc position peaked at $31M in Q2 2021.
  • 0 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2025.

Based on Vanguard Group's 13F filing for Q1 2025, filed 9 May 2025.